castle biosciences stock zacks

As of late it has definitely been a great time to be an investor in Castle Biosciences Inc. Get prepared with the key.

Document

Find the latest Castle Biosciences Inc.

. CSTL delivered earnings and revenue surprises of -1940 and 687 respectively for the quarter ended March 2022. Is currently rated as a Zacks Rank 1 and we are expecting an above average return from the CSTL shares relative to the. At Castle Biosciences we promise to treat your data with respect and will not share your information with any third party.

Zacks Investment Research upgraded shares of Castle Biosciences NASDAQCSTL Get Rating from a sell rating to a hold rating in a research note issued to. Castle Biosciences Inc. For the last reported quarter it was expected that Castle Biosciences Inc.

This compares to loss of 047 per. CSTL delivered earnings and revenue surprises of 8966 and 2267 respectively for the quarter ended June 2022. For the last reported quarter it was expected that Castle Biosciences Inc.

You can unsubscribe to any of the investor alerts you are. Get the latest chart with broker recommendations from Zacks Investment Research. Over the past three months the Zacks Consensus Estimate for the company has increased 664.

Castle Biosciences Inc. This compares to loss of 008 per. Beta is a widely used stock evaluation measure.

For Castle Biosciences Inc the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Do the numbers hold. And a stocks price usually doesnt keep moving.

CSTL stock quote history news and other vital information to help you with your stock trading and investing. The stock has moved higher by 23 in the past month while it is. CSTL came out with a quarterly loss of 034 per share versus the Zacks Consensus Estimate of a loss of 029.

CSTL doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. CSTL shares ended the last trading session 53 higher at 6542. Analysts have been steadily raising their estimates for Castle Biosciences Inc.

Find the latest Peg Ratio TTM for Castle Biosciences CSTL. Castle Biosciences Inc. Would post a loss of 006 per share when it actually produced a loss of 023 delivering a surprise of.

CSTL came out with a quarterly loss of 077 per share versus the Zacks Consensus Estimate of a loss of 070. Castle Biosciences Inc. Do the numbers hold clues to what.

Zacks proprietary data indicates that Castle Biosciences Inc. C astle Biosciences Inc. Would post a loss of 006 per share when it actually produced a loss of 023 delivering a surprise of.

Castle Biosciences broker recommendation chart. Castle Biosciences Inc which belongs to the Zacks Medical - Biomedical and Genetics industry posted revenues of 3701 million for the quarter ended September 2022. Peg Ratio TTM is a widely used stock evaluation measure.

CSTL - Free Report. Find the latest Beta for Castle Biosciences CSTL. Castle Biosciences Inc.

Find the latest Shareholders Equity Quarterly for Castle Biosciences CSTL. The jump came on an impressive volume with a higher-than-average number of. Shareholders Equity Quarterly is a widely used stock evaluation measure.

Castle Biosciences Stock Info